Why do anti-angiogenic therapies fail in #OralCancer?
This study identifies the IL-33/ST2L–TRAF6/NF-κB axis as a driver of #VasculogenicMimicry, revealing TRAF6 inhibition as a strategy to boost bevacizumab efficacy.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...